Clinical trials: Androgens
Prostate Cancer Adenocarcinoma in Situ
A Neoadjuvant Study of Androgen Ablation Combined With Cyclophosphamide and GVAX Vaccine for Localized Prostate Cancer
This research is being done to see if an investigational prostate cancer vaccine, called GVAX, can safely be given together with a single intravenous injection of a drug called cyclophosphamide to men that will undergo surgery to…
- Trial name
- NCT01696877
- Testing
- degarelix acetate, Cyclophosphamide, GVAX
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Polycystic Ovary Syndrome
A Study of Safety and Efficacy of Tildacerfont in Females With Polycystic Ovary Syndrome and Elevated Adrenal Androgens
An investigation of the safety and efficacy of tildacerfont in women with PCOS and elevated adrenal androgens
- Trial name
- NCT05370521
- Testing
- Tildacerfont
- Where
- 21 sites in United States
- Volunteers
- 27 people
- Sponsor
- Spruce Biosciences
Prostate Cancer
Androgen Deprivation Therapy +/- Bevacizumab for PSA Recurrence of Prostate Cancer After Definitive Local Therapy
The purpose of this research study is to assess the efficacy of antiangiogenic therapy (bevacizumab) and androgen deprivation versus androgen deprivation alone at the time of minimal systemic disease (based on rising PSA without…
- Trial name
- NCT00776594
- Testing
- Androgen Deprivation Therapy, bicalutamide, bevacizumab
- Where
- 8 sites in United States
- Volunteers
- 102 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
Zometa on Bone Mineral Density in Prostate Cancer Patients Undergoing Androgen Ablation Therapy
The purpose of this research is to determine the effect of timing of Zometa® administration on bone mineral density of the lumbar spine and femoral neck in men undergoing androgen deprivation therapy for prostate adenocarcinoma.
- Trial name
- NCT00582556
- Testing
- Zometa
- Where
- United States
- Volunteers
- 44 people
- Sponsor
- University of Wisconsin, Madison
Prostate Cancer
Improving Quality of Life of Prostate Cancer Survivors With Androgen Deficiency
The purpose of this phase II trial is to determine the efficacy and safety of testosterone replacement therapy (TRT) in improving the symptoms of androgen deficiency and health-related quality of life in men with prostate cancer…
- Trial name
- NCT03716739
- Testing
- Testosterone Cypionate 100 MG/ML
- Where
- 3 sites in United States
- Volunteers
- 136 people
- Sponsor
- Dana-Farber Cancer Institute
Prostate Cancer
A Parallel Group Comparison of the Efficacy and Safety of Degarelix at Two Different Dosing Regimens in Patients With Prostate Cancer
The purpose of the study was to contribute, along with other such dose-finding studies, to the identification of the most effective treatment regimen for a one month depot injection of degarelix in the treatment of prostate…
- Trial name
- NCT00116779
- Testing
- Degarelix
- Where
- 35 sites in United States, Canada
- Volunteers
- 127 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Efficacy and Safety of Leuprolide Acetate 22.5 mg Depot in Treatment of Prostate Cancer
Some patients with prostate cancer benefit from androgen deprivation therapy which reduces levels of testosterone. Leuprolide is a synthetic Luteinizing hormone releasing hormone (LHRH) analogue which upon administration can…
- Trial name
- NCT01415960
- Testing
- Leuprolide acetate 22.5 mg depot, GP-Pharm SA
- Where
- 25 sites in United States
- Volunteers
- 163 people
- Sponsor
- GP-Pharm
Healthy
Effect of Dihydrotestosterone (DHT) on Prostate Tissue [Short Title: DHT-3]
The purpose of this research study is to understand the effects of a male hormone normally made in the body called Dihydrotestosterone (DHT) on the prostate gland that is located under the bladder.
- Trial name
- DHT-3 (NCT00490022)
- Testing
- Dihydrotestosterone (DHT) gel (0.7%)
- Where
- United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Washington
Prostate Cancer
Tecemotide (L-BLP25) in Prostate Cancer
This study examines tecemotide (L-BLP25) in combination with standard treatment for prostate cancer.
- Trial name
- NCT01496131
- Testing
- Radiation therapy, Goserelin, Cyclophosphamide
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- EMD Serono
Prostate Cancer
Study Investigating the Pharmacokinetics, Pharmacodynamics and Safety of FE200486
Population pharmacokinetic and pharmacodynamic data from Study FE200486 CS06 and FE200486 CS02 provided further knowledge of the optimal dose regimens for FE200486 (degarelix).
- Trial name
- NCT00117949
- Testing
- Degarelix
- Where
- 12 sites in United States
- Volunteers
- 82 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
GTx-758 on Serum Prostate-specific Antigen (PSA) in Men With Castrate Resistant Prostate Cancer
The purpose of this study is to assess the effect of GTx-758 on Serum Prostate-specific antigen (PSA) levels in men with castrate resistant prostate cancer who are maintained on androgen deprivation therapy (Serum PSA response…
- Trial name
- NCT01420861
- Testing
- GTx-758
- Where
- 7 sites in United States
- Volunteers
- 18 people
- Sponsor
- GTx
Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma
Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors
This research study is studying a combination of hormonal therapy, chemotherapy, and immunotherapy as a possible treatment for metastatic hormone-sensitive prostate cancer.
- Conditions
- Hormone Sensitive Prostate Cancer, Prostate Adenocarcinoma, Metastasis Prostate Adenocarcinoma
- Trial name
- NCT04126070
- Testing
- Androgen Deprivation Therapy, Nivolumab, Docetaxel
- Where
- 6 sites in United States
- Volunteers
- 47 people
- Sponsor
- Xiao X. Wei, MD
Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7
Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
This phase II trial studies how well giving bicalutamide with or without Akt inhibitor MK2206 works in treating patients with previously treated prostate cancer. Androgens can cause the growth of prostate cancer cells.
- Conditions
- Recurrent Prostate Carcinoma, Stage I Prostate Cancer AJCC v7, Stage IIA Prostate Cancer AJCC v7, Stage IIB Prostate Cancer AJCC v7
- Trial name
- NCT01251861
- Testing
- Akt Inhibitor MK2206, Bicalutamide, Clinical Observation
- Where
- 198 sites in United States, Ireland
- Volunteers
- 108 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Hormone-Sensitive Prostate Cancer
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China Extension
This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus Androgen Deprivation Therapy (ADT) versus placebo plus enzalutamide plus ADT in Chinese participants with mHSPC.
- Trial name
- NCT04934722
- Testing
- Pembrolizumab, Enzalutamide, Androgen Deprivation Therapy (ADT)
- Where
- 24 sites in China
- Volunteers
- 186 people
- Sponsor
- Merck Sharp & Dohme LLC
Prostate Cancer
Cabozantinib and Androgen Ablation in Patients With Androgen-Dependent Metastatic Prostate Cancer
The goal of this clinical research study is learn if adding cabozantinib (also known as XL184) to hormonal therapy can help to control prostate cancer. The safety of this drug will also be studied.
- Trial name
- NCT01630590
- Testing
- Cabozantinib, Androgen Ablation Therapy
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- M.D. Anderson Cancer Center
Prostate Cancer
Provenge® (Sipuleucel-T) Active Cellular Immunotherapy Treatment of Metastatic Prostate Cancer After Failing Hormone Therapy
Provenge is an investigational product designed to activate a man's own antigen presenting cells, a type of immune cell, so that they can detect prostate cancer cells and initiate an immune response against them.
- Trial name
- NCT00065442
- Testing
- Sipuleucel-T
- Where
- 71 sites in United States, Canada
- Volunteers
- 512 people
- Sponsor
- Dendreon
Pressure Ulcer
Oxandrolone to Heal Pressure Ulcers
This study is designed to determine whether the use of oxandrolone, an anabolic steroid, can heal pressure ulcers in persons with spinal cord injury (SCI).
- Trial name
- NCT00101361
- Testing
- Oxandrolone
- Where
- 16 sites in United States, Puerto Rico
- Volunteers
- 212 people
- Sponsor
- US Department of Veterans Affairs
Prostate Cancer
Exisulind and Intermittent Androgen Suppression (ADT) in Biochemical Relapsed Prostate Cancer
The purpose of this research study is to determine if an investigational drug called Exisulind will extend the "off-treatment" period of patients receiving Intermittent Androgen Suppression (ADT).
- Trial name
- NCT00283803
- Testing
- Exisulind, luteinizing hormone-releasing hormone (LHRH) agonist, Antiandrogen
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- University of Washington
Prostate Cancer
Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer
This was an extension study for the study FE200486 CS14 (NCT00116779). Each participant was to be treated until he was discontinued or withdrawn from the study, or a marketing authorization for degarelix had been obtained.
- Trial name
- NCT00117286
- Testing
- Degarelix
- Where
- 22 sites in United States, Canada
- Volunteers
- 57 people
- Sponsor
- Ferring Pharmaceuticals
Prostate Cancer
Investigating Efficacy and Safety of Two Degarelix Three-Month Dosing Regimens in Patients With Prostate Cancer Requiring Androgen Ablation Therapy
The study will have two treatment groups, evaluating two Degarelix doses. First dose is the initial dose followed by a maintenance dose given every three months.
- Trial name
- NCT00468286
- Testing
- Degarelix
- Where
- 29 sites in United States, Canada and 3 more
- Volunteers
- 133 people
- Sponsor
- Ferring Pharmaceuticals